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Abstract
Author Manuscript

Background—Therapeutic hypothermia is recommended for comatose adults after witnessed
out-of-hospital cardiac arrest, but data about this intervention in children are limited.
Methods—We conducted this trial of two targeted temperature interventions at 38 children’s
hospitals involving children who remained unconscious after out-of-hospital cardiac arrest. Within
6 hours after the return of circulation, comatose patients who were older than 2 days and younger
than 18 years of age were randomly assigned to therapeutic hypothermia (target temperature,
33.0°C) or therapeutic normothermia (target temperature, 36.8°C). The primary efficacy outcome,
survival at 12 months after cardiac arrest with a Vineland Adaptive Behavior Scales, second
edition (VABS-II), score of 70 or higher (on a scale from 20 to 160, with higher scores indicating
better function), was evaluated among patients with a VABS-II score of at least 70 before cardiac
arrest.
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Results—A total of 295 patients underwent randomization. Among the 260 patients with data
that could be evaluated and who had a VABS-II score of at least 70 before cardiac arrest, there
was no significant difference in the primary outcome between the hypothermia group and the
normothermia group (20% vs. 12%; relative likelihood, 1.54; 95% confidence interval [CI], 0.86
to 2.76; P = 0.14). Among all the patients with data that could be evaluated, the change in the
VABS-II score from baseline to 12 months was not significantly different (P = 0.13) and 1-year
survival was similar (38% in the hypothermia group vs. 29% in the normothermia group; relative
likelihood, 1.29; 95% CI, 0.93 to 1.79; P = 0.13). The groups had similar incidences of infection
and serious arrhythmias, as well as similar use of blood products and 28-day mortality.
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Conclusions—In comatose children who survived out-of-hospital cardiac arrest, therapeutic
hypothermia, as compared with therapeutic normothermia, did not confer a significant benefit in
survival with a good functional outcome at 1 year. (Funded by the National Heart, Lung, and
Blood Institute and others; THAPCA-OH ClinicalTrials.gov number, NCT00878644.)
Out-of-hospital cardiac arrest in children often results in death or in poor long-term
functional outcome in survivors.1–3 In 2002, two trials involving adults showed that
therapeutic hypothermia improved neurologic outcomes in comatose survivors after out-ofhospital cardiac arrest with ventricular fibrillation or ventricular tachycardia.4,5 International
guidelines recommend therapeutic hypothermia for adults with out-of-hospital cardiac arrest
who have similar characteristics.6,7 Recently, another trial involving adults after out-ofhospital cardiac arrest showed that therapeutic hypothermia with the use of a target
temperature of 33°C, as compared with actively maintained therapeutic normothermia
(36°C), did not improve outcomes.8 The fundamental difference between this recent trial
and the earlier 2002 trials was the active intervention to prevent fever in the comparison
group of patients who were treated with normothermia.4,5,8
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Published results of randomized trials of therapeutic hypothermia in children after out-ofhospital cardiac arrest are lacking.9 In observational studies, therapeutic hypothermia has not
been associated with improved outcomes in children after cardiac arrest.10–12 Moreover, one
trial involving pediatric patients with traumatic brain injury showed a trend toward increased
mortality in the hypothermia group.13 There are significant differences between adult and
pediatric populations with out-of-hospital cardiac arrest, and results cannot be generalized
between age groups.14 We report results of the Therapeutic Hypothermia after Pediatric
Cardiac Arrest Out-of-Hospital (THAPCA-OH) trial, which compared the efficacy of
therapeutic hypothermia (target temperature, 33.0°C) with that of therapeutic normothermia
(target temperature, 36.8°C).15,16
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METHODS
STUDY DESIGN AND OVERSIGHT
This randomized clinical trial, which was conducted in pediatric intensive care units (ICUs)
at 38 children’s hospitals in the United States and Canada, involved children who were
admitted after out-of-hospital cardiac arrest. The rationale, study design, outcome selection
process, protocol summary, and 12-month pilot vanguard phase have been described
previously.15–17
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The trial was funded by the National Heart, Lung, and Blood Institute (NHLBI). The
protocol was designed by the first, third, and last authors. The institutional review board at
each participating site and the data coordinating center at the University of Utah (see the
Supplementary Appendix, available with the full text of this article at NEJM.org) approved
the protocol and informed-consent documents.
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The site research coordinators listed in the Supplementary Appendix collected all the data,
and statisticians at the data coordinating center performed all the analyses. Details of site
training, data management, and site monitoring are provided in the Supplementary
Appendix. An independent data and safety monitoring board that was appointed by the
NHLBI conducted interim safety and efficacy analyses.18 All the authors vouch for the
accuracy and completeness of the submitted data, the third and last authors vouch for the
data management and statistical analyses, and all the authors vouch for the fidelity of this
report to the study protocol, which is available at NEJM.org.
PATIENT POPULATION
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Children older than 48 hours and younger than 18 years of age were eligible for inclusion in
the study if they had a cardiac arrest requiring chest compressions for at least 2 minutes and
remained dependent on mechanical ventilation after the return of circulation. Major
exclusion criteria were the inability to undergo randomization for any reason within 6 hours
after the return of circulation, a score of 5 or 6 on the Glasgow Coma Scale motor-response
subscale (on which scores range from 1 to 6, with lower scores indicating reduced levels of
function), the decision by the clinical team to withhold aggressive treatment, and major
trauma associated with the cardiac arrest. A full listing of the exclusion criteria is provided
in the Supplementary Appendix. Written informed consent from a parent or legal guardian
was obtained for each participant.
RANDOMIZATION AND INTERVENTION
Eligible patients were randomly assigned in a 1:1 ratio to either therapeutic hypothermia or
therapeutic normothermia. Randomization was performed with the use of permuted blocks
stratified according to clinical center and age at entry (<2 years, 2 to <12 years, and ≥12
years).

Author Manuscript

Targeted temperature management was actively maintained for 120 hours in each group.
Children who were assigned to therapeutic hypothermia were pharmacologically paralyzed
and sedated, and a Blanketrol III temperature management unit (Cincinnati Sub-Zero) was
used, with blankets applied anteriorly and posteriorly, to achieve and maintain a core
temperature of 33.0°C (range, 32.0 to 34.0) for 48 hours. The children were then rewarmed
over a period of 16 hours or longer to a target temperature of 36.8°C (range, 36.0 to 37.5);
this temperature was actively maintained throughout the remainder of the 120-hour
intervention period. Children who were randomly assigned to therapeutic normothermia
received identical care except that the core temperature was actively maintained with the
cooling unit at 36.8°C (range, 36.0 to 37.5) for 120 hours.
Dual monitoring of the central temperature (esophageal, rectal, or bladder temperature) and
an automatic mode on the temperature management unit were used for all the patients. The
N Engl J Med. Author manuscript; available in PMC 2015 November 14.
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probe connected to the cooling unit was designated to be the primary probe; the other probe
was connected to the bedside monitor for safety backup. In three patients who received
extracorporeal membrane oxygenation (ECMO) at the time of randomization, ECMO was
used for temperature control. All other aspects of clinical care were determined by the
clinical teams.
OUTCOMES

Author Manuscript

The primary outcome was survival with a good neurobehavioral outcome at 12 months of
follow-up. A good neurobehavioral outcome was defined as an age-corrected standard score
of 70 or higher on a scale of 20 to 160 on the Vineland Adaptive Behavior Scales, second
edition (VABS-II).19 The VABS-II has an age-corrected mean score of 100 and a standard
deviation of 15; higher scores indicate better function. The VABS-II data were collected
centrally at the Kennedy Krieger Institute by means of telephone interviews conducted by a
trained interviewer who was unaware of the treatment assignments.
As prespecified in the trial protocol, enrolled children whose reported VABS-II scores were
less than 70 before cardiac arrest (on the basis of data from a standardized caregiver
questionnaire completed by a parent or guardian at each site within 24 hours after
randomization) were not included in the primary efficacy analysis. Patients for whom no
baseline VABS-II score was available were considered to be eligible for the primary
analysis if the baseline Pediatric Overall Performance Category (POPC) and Pediatric
Cerebral Performance Category (PCPC) scores20 were in the normal or mild disability
category.17,21 Both scales range from 1 to 6, with lower scores indicating less disability;
patients with scores of either 1 or 2 on both scales were eligible for the primary analysis.
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Secondary outcomes were survival 12 months after cardiac arrest and change in
neurobehavioral function, measured as the difference between the baseline level before
cardiac arrest and the 12-month measurement on the VABS-II. For the latter, patients who
had died and patients with the lowest possible VABS-II score were assigned the worst
possible outcomes, regardless of baseline function.
A global cognitive score that was based on results of on-site neuropsychological testing was
a tertiary outcome (see the Supplementary Appendix). Safety outcomes included the
incidences of blood-product use, infection, and serious arrhythmias through 7 days and 28day mortality. Details of the methods used for the assessment of outcomes are provided in
the Supplementary Appendix.
STATISTICAL ANALYSIS

Author Manuscript

The target sample size was calculated on the basis of an absolute effect size of 15 to 20%,
with an estimated primary outcome rate of 15 to 35% in the normothermia group. Assuming
that 5% of the patients would be excluded owing to a baseline neurologic deficit and that 5%
of patients would be lost to follow-up, we estimated that 276 patients would need to be
enrolled to provide the study with 85% power to detect a 20% treatment effect.
The efficacy analysis for the primary outcome was performed with the use of a prespecified
modified intention-to-treat approach, excluding children with poor neurobehavioral function
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before cardiac arrest, as noted above. Secondary efficacy outcomes were analyzed in all the
children. Safety analyses were performed according to the treatment received in treated
patients only. The primary outcome and 12-month mortality were compared between the
treatment groups with the use of a Cochran–Mantel–Haenszel test stratified according to age
category.
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The change in the VABS-II score was analyzed with the use of van Elteren’s modification of
the Mann–Whitney test,22 with stratification according to age category, treatment of death as
the worst outcome, and treatment of the lowest possible VABS-II score at 1 year as the
second worst outcome. An alpha level of 0.05 was set for the primary analysis, and an alpha
level of 0.025 was set for each of the two formal secondary analyses, with two-sided tests
used in all instances. The probability of survival to 1 year was evaluated by comparing
survival curves over time between treatment groups with the use of a log-rank test stratified
according to age category. All analyses were performed with the use of SAS software,
version 9.3 (SAS Institute).

RESULTS
PATIENTS

Author Manuscript

Between September 1, 2009, and December 31, 2012, we identified 1355 patients who were
screened for eligibility and met the trial inclusion criteria (Fig. 1). Of these patients, 475
were eligible to enroll in the study. The families of 411 of these patients were approached
for consent, 299 families consented, and 295 patients underwent randomization at 36 sites in
the United States and Canada (2 sites did not enroll any patients). Of the patients who
underwent randomization to targeted temperature management, 155 were assigned to
therapeutic hypothermia and 140 were assigned to therapeutic normothermia. A total of 3
patients who were assigned to therapeutic hypothermia did not receive an intervention, and 1
patient assigned to therapeutic normothermia received hypothermia therapy.
Of the 295 patients who underwent randomization, 13 in the hypothermia group and 12 in
the normothermia group were ineligible for the primary outcome analysis owing to baseline
VABS-II scores that were less than 70, or POPC or PCPC scores that were 3 or higher. At
12 months, vital status was not known in 4 patients in each group, and 2 additional surviving
children in the normothermia group did not undergo VABS-II testing (Fig. 1). Therefore,
260 patients had data that could be evaluated for the primary outcome.
CHARACTERISTICS AT BASELINE AND TEMPERATURE INTERVENTION
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The characteristics of the patients in the hypothermia group and those in the normothermia
group were similar at baseline (Table 1, and Table S1 in the Supplementary Appendix). The
median age of the patients was 2 years; two thirds of the patients were male. Bystanders
witnessed the cardiac arrest in 39% of the patients and performed cardiopulmonary
resuscitation in 66% of them. The initial rhythm was ventricular fibrillation or ventricular
tachycardia in 8% of the patients. Baseline functional status based on the VABS-II, PCPC,
and POPC scores is shown in Table S2 in the Supplementary Appendix.
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The median time from the return of circulation to the initiation of treatment was 5.9 hours
(interquartile range, 5.2 to 6.7) in the hypothermia group and 5.8 hours (interquartile range,
5.0 to 6.4) in the normothermia group. Figure 2 shows the primary central (core)
temperatures recorded for the two groups. Additional information regarding temperature
control is provided in the Supplementary Appendix.
OUTCOMES
The proportion of survivors with VABS-II scores of 70 or more at 12 months was not
significantly different between the two groups (20% in the hypothermia group vs. 12% in
the normothermia group; relative likelihood, 1.54; 95% confidence interval [CI], 0.86 to
2.76; P = 0.14) (Table 2). Sensitivity analyses, including a per-protocol analysis and
analyses with imputation of missing data, did not alter the primary-outcome result (see the
Supplementary Appendix).
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The secondary outcome of change in the VABS-II score from baseline to 12 months also did
not differ significantly between the two groups (P = 0.13). The overall proportion of patients
with 12-month VABS-II scores that did not decrease by more than 15 points (1 SD) of their
baseline measurements was similar in the hypothermia group and the normothermia group
(14% and 13%) (Table 2).
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Mortality among all patients who underwent randomization and whose vital status was
known (287 of 295 patients [97%]) was assessed at 12 months. Survival at 1 year did not
differ significantly between the groups (38% in the hypothermia group vs. 29% in the
normothermia group; relative likelihood, 1.29; 95% CI, 0.93 to 1.79; P = 0.13) (Table 2).
Survival over time was significantly longer with therapeutic hypothermia than with
therapeutic normothermia (mean survival, 149±14 days vs. 119±14 days; P = 0.04 for the
comparison of survival between the two treatment groups by means of the log-rank test)
(Fig. S1 in the Supplementary Appendix). The primary cause of death was brain death or
withdrawal of life-sustaining therapy owing to a poor neurologic prognosis in the majority
of patients in the two groups (82% of the patients in the hypothermia group and 79% of the
patients in the normothermia group) (Table S3 in the Supplementary Appendix).
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Data on global cognitive functioning in survivors are shown in Table S4 in the
Supplementary Appendix. Results of the Early Learning Composite score from the Mullen
Scales of Early Learning23 did not differ significantly between the survivors in the
hypothermia group and those in the normothermia group; there were also no significant
between-group differences in the IQ score24 distributions on the Wechsler Abbreviated
Scale of Intelligence or in the combined categories from both the Mullen and the Wechsler
tests.
SAFETY
The incidences of infection, bleeding, and serious arrhythmias within 7 days after
randomization were similar in the 153 patients who received hypothermia therapy and the
139 who received normothermia therapy (Table 3). Mortality at 28 days was also not
significantly different in the two groups (57% in the hypothermia group vs. 67% in the
normothermia group, P = 0.08). Additional data regarding adverse events are provided in
N Engl J Med. Author manuscript; available in PMC 2015 November 14.

Moler et al.

Page 7

Author Manuscript

Table S5 in the Supplementary Appendix. Hypokalemia and thrombocytopenia occurred
more frequently in the hypothermia group, and renal-replacement therapy was used more
often in the normothermia group.

DISCUSSION

Author Manuscript

The THAPCA-OH trial evaluated the efficacy of therapeutic hypothermia (targeted
temperature management at 33.0°C) and therapeutic normothermia (targeted temperature
management at 36.8°C) to improve outcomes after out-of-hospital cardiac arrest in children.
There was no significant between-group difference in the primary outcome of survival with
a good neurobehavioral outcome (VABS-II composite score of ≥70) at 12 months. The
secondary outcome, the change in the VABS-II score from baseline to 1 year, did not differ
between the groups; the proportion of children with VABS-II scores that decreased no more
than 15 points (1 SD) from their baseline scores was similar in the two groups. All-cause
mortality at 1 year also did not differ significantly between the two groups, although
survival analysis through 365 days showed a significant difference in survival time in favor
of therapeutic hypothermia.
One important potential limitation of the trial is that, on the basis of the observed confidence
limits for treatment differences, a potentially important clinical benefit cannot be ruled out
despite the lack of a significant difference in the primary outcome measure. A larger trial
might have detected or rejected a smaller intervention effect. Indeed, there was a significant
difference in survival time with therapeutic hypothermia, although this was a secondary
outcome measure.
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Other trial limitations should also be noted. Caregivers and research staff in the ICU could
not be unaware of the treatment assignments of the patients, although the primary outcome
assessments were blinded. We could not rule out the possibility of earlier death or
determination by clinical teams of futility in the normothermia group. Patients in the
hypothermia group may have survived longer because prognostic assessments were delayed
until normothermia was achieved. For logistical reasons, we did not conduct a preclinical
trial site phase-in or use only high-enrolling sites; such strategies have been suggested in
other hypothermia trials.13,25–28
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Our overall findings are consistent with those of a previous clinical trial investigating the
efficacy of therapeutic hypothermia (target temperature, 33°C) versus therapeutic
normothermia (target temperature, 36°C) in adult survivors of out-of-hospital cardiac
arrest.8 In contrast to the earlier trials,4,5 in the recent trial involving adults, fever was
prevented in the normothermia group through an active intervention similar to that in our
normothermia group.8 The duration of temperature control, however, was much longer in
our trial (120 hours vs. 36 hours). Moreover, the characteristics of our population of children
with out-of-hospital cardiac arrest differed markedly from the population of adults with outof-hospital cardiac arrest, as expected. The leading cause of cardiac arrest was a respiratory
condition in 72% of our patients, as compared with a presumed cardiac cause in all patients
in the recent trial involving adults.8 Our trial also had a much lower proportion of patients
with shockable rhythms (8% vs. 80%).8

N Engl J Med. Author manuscript; available in PMC 2015 November 14.
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One possible explanation for the difference between the early trials of therapeutic
hypothermia and the more recent studies is that controlled normothermia (which was used in
the more recent trials) may be beneficial in patients with cardiac arrest. Fever commonly
occurs after hypoxic–ischemic brain injury.3,29–31 Initial trials of therapeutic hypothermia
for neonatal asphyxial encephalopathy and adult cardiac arrest did not prevent fever in
control groups.4,32–34 A recent trial of cooling versus normal temperature control in neonatal
patients at high risk for neurologic injury who were receiving ECMO support showed no
difference in outcome or adverse effects.35 Studies of the usefulness of therapeutic
hypothermia for traumatic brain injury in children have not shown efficacy,36 and one
showed a trend toward higher mortality.13
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Unanswered questions remain concerning the potential role of targeted temperature
management in children after cardiac arrest. Alternative durations of therapeutic
hypothermia temperature control (longer or shorter), different depths of temperature control
(higher or lower), and a different therapeutic window for initiating therapeutic hypothermia
(shorter) are modifications that might be considered for future study. Modification of
inclusion and exclusion criteria and a combination of targeted temperature management with
neuroprotective agents might also be considered in future trials of treatment involving
children after cardiac arrest.37 We are currently evaluating targeted temperature
management in children after in-hospital cardiac arrest (ClinicalTrials.gov number,
NCT00880087); this represents a pathophysiologically distinct population, and the efficacy
of the interventions may differ.38
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In conclusion, in comatose children who survive of out-of-hospital cardiac arrest,
therapeutic hypothermia, as compared with therapeutic normothermia, did not confer a
significant benefit with respect to survival with good functional outcome at 1 year. Survival
at 12 months did not differ significantly between the treatment groups.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Enrollment, Randomization, and Treatment

Scores on the Glasgow Coma Scale (GCS) motor-response subscale range from 1 to 6, with
lower scores indicating reduced levels of function. Scores on the Pediatric Overall
Performance Category (POPC) and Pediatric Cerebral Performance Category (PCPC) scales
range from 1 to 6, with lower scores indicating less disability. Scores on the Vineland
Adaptive Behavior Scales, second edition (VABS-II), range from 20 to 160, with higher
scores indicating better function. CNS denotes central nervous system, ICU intensive care
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unit, ITT intention to treat, and THAPCA Therapeutic Hypothermia after Pediatric Cardiac
Arrest.
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Figure 2. Temperature of Patients during 120 Hours of Targeted Temperature Management,
According to Treatment Group

The temperature curves show the means of all primary temperature readings within each
time interval (for example, all primary temperature readings from 22 to 26 hours after the
initiation of treatment are counted in the category “24 hours since initiation of treatment”).
The I bars indicate ±2 SD from the mean temperature within each time interval. Time points
for normothermia are slightly shifted to prevent overlap. Temperatures recorded after early
termination of treatment are not included in this analysis.
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Author Manuscript

Baseline Characteristics of the Patients before Randomization.*
Hypothermia Group
(N = 155)

Characteristic

Normothermia Group
(N = 140)

Demographic characteristics
Age — yr
Median

2.1

1.6

0.6–10.1

0.4–7.0

<2 yr

  76 (49)

  73 (52)

2 to <12 yr

  48 (31)

  45 (32)

≥12 yr

  31 (20)

  22 (16)

102 (66)

  94 (67)

  81 (52)

  71 (51)

Lung or airway disease

  33 (21)

  34 (24)

Neurologic condition

  30 (19)

  19 (14)

Gastrointestinal disorder

  19 (12)

  22 (16)

Prenatal condition

  15 (10)

  22 (16)

14 (9)

  21 (15)

  34 (22)

  37 (26)

111 (72)

102 (73)

14 (9)

  18 (13)

Interquartile range
Age category — no. (%)

Male sex — no. (%)

Author Manuscript

Medical history — no. (%)
No preexisting medical condition
Preexisting medical condition

Congenital heart disease
Other
Characteristics of the cardiac arrest
Primary cause of the cardiac arrest — no. (%)

Author Manuscript

Respiratory event
Cardiovascular event
Other

11 (7)

  4 (3)

  19 (12)

  16 (11)

Bystander witnessed cardiac arrest — no./total no. (%)

58/145 (40)

51/136 (38)

Bystander performed CPR — no./total no. (%)

101/149 (68)

85/134 (63)

  85 (55)

  87 (62)

  9 (6)

10 (7)

  25 (16)

  18 (13)

Unknown

Initial rhythm noted by EMS or hospital — no. (%)
Asystole
Bradycardia
Pulseless electrical activity
Ventricular fibrillation or tachycardia

Author Manuscript

Unknown

14 (9)

  9 (6)

  22 (14)

  16 (11)

3.0

2.0

0.0–7.0

0.0–8.0

Time from cardiac arrest to CPR in 82 patients — min
Median
Interquartile range
Duration of CPR in 186 patients — min
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Characteristic

Author Manuscript

Median
Interquartile range
First hospital patient arrived at was the study hospital — no. (%)
Chest compressions still required at time of arrival at first hospital — no./total no. (%)

Hypothermia Group
(N = 155)

Normothermia Group
(N = 140)

23.0

28.0

15.0–35.0

19.0–45.0

  45 (29)

  43 (31)

97/152 (64)

100/137 (73)

2.0

1.0

0.0–3.0

0.0–2.0

No. of doses of epinephrine
Administered by EMS in 270 patients†
Median
Interquartile range
Administered at hospital in 289 patients†
Median
Interquartile range

Author Manuscript

1.0

2.0

0.0–3.0

0.0–4.0

3.0

3.0

2.0–4.5

2.0–5.0

All doses administered by EMS and at hospital in 265 patients
Median
Interquartile range
*
CPR denotes cardiopulmonary resuscitation, and EMS emergency medical services.
†

P<0.05 for the comparison between the two groups.

Author Manuscript
Author Manuscript
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Author Manuscript
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11/151 (7)  
21/151 (14)

≤15 points or improved

17/134 (13)

4/134 (3)

15/134 (11)

1/134 (1)

97/134 (72)

39/136 (29)

15/122 (12)

8/122 (7)

11/122 (9)  

88/122 (72)

15/122 (12)

9.1 (−1.8 to 19.9)

7.3 (−1.5 to 16.1)

percentage points (95% CI)

Risk Difference

1.29 (0.93 to 1.79)

1.54 (0.86 to 2.76)

Relative Likelihood (95% CI)

  0.13**

0.13†

0.14‡

0.14†

P Value

Profound disability was defined as a VABS-II score of less than 45 or the lowest possible score.

§

The P value was calculated by means of the Mann–Whitney test on the basis of the 1-year continuous VABS-II score, stratified according to age category. Deceased patients and those with the lowest
possible VABS-II score were assigned ranks of −2000 and −1000, respectively (i.e., the worst possible scores).

‡

The P value was calculated by means of the Cochran–Mantel–Haenszel test, with adjustment for age category.

†

The primary outcome was evaluated in patients with a baseline Vineland Adaptive Behavior Scales, second edition (VABS-II), score of 70 or higher at 12 months (scores on the VABS-II range from 20 to
160, with higher scores indicating better function). The secondary outcomes were evaluated in all patients with available data. Denominators reported are for patients whose outcomes were known. CI
denotes confidence interval.

*

19/151 (13)

16–30 points

6/151 (4)

94/151 (62)

>30 points

Decrease in VABS-II score

Lowest possible VABS-II score

Death

1-yr change in VABS-II score from baseline

Alive at 1 yr

57/151 (38)

27/138 (20)

Good functional status‖

Secondary outcomes

8/138 (6)

16/138 (12)

87/138 (63)

27/138 (20)

Moderate-to-severe¶

Profound§

Disability

Death

Detailed supportive analysis

Alive with VABS-II score ≥70 at 1 yr

Primary outcome

Normothermia Group

no./total no. (%)

Hypothermia Group

Author Manuscript

Outcome

Author Manuscript

Primary and Secondary Outcomes.*

Author Manuscript

Table 2
Moler et al.
Page 17
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Author Manuscript

The P value was calculated by means of the Mann–Whitney test on the basis of the continuous change in VABS-II score, stratified according to age category. Deceased patients and those with the lowest
possible VABS-II score were assigned ranks of −2000 and −1000, respectively (i.e., the worst possible scores).

**

Good functional status was defined as a VABS-II score of 70 or higher.

Moderate-to-severe disability was defined as a VABS-II score of 45 to 69.

Author Manuscript

‖

Author Manuscript
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Table 3

Author Manuscript

Safety Outcomes within 7 Days after Randomization and 28-Day Mortality.
Hypothermia Group
(N = 153)

Normothermia Group
(N = 139)

P Value*

83/153 (54)

74/138 (54)

0.92

Cryoprecipitate

13/153 (8)  

12/137 (9)  

0.94

Fresh-frozen plasma

50/153 (33)

41/138 (30)

0.59

Packed red cells or whole blood

65/153 (42)

59/137 (43)

0.92

Platelets

19/153 (12)

12/137 (9)  

0.32

17/153 (11)

13/137 (9)  

0.66

6/153 (4)

5/137 (4)

0.91

4/153 (3)

2/137 (1)

0.53

1/153 (1)

0/137     

0.53

5/153 (3)

5/137 (4)

0.86

7/153 (5)

2/137 (1)

0.14

70/153 (46)

54/137 (39)

0.28

Outcome
Blood-product use — no./total no. (%)
Any
Type

Arrhythmias — no./total no. (%)
Serious

Author Manuscript

Type
Asystole
Atrial (supraventricular tachycardia, atrial flutter, junctional ectopic
tachycardia)
Pulseless electrical activity
Ventricular (sustained ventricular tachycardia >30 sec, ventricular
fibrillation, torsades)
Other
Culture-proven infections
Any — no./total no. (%)

Author Manuscript

No. of infections

109

76

No. of days at risk

978

765

11.1 (9.2–13.4)

9.9 (7.8–12.4)

 0.46†

87/153 (57)

93/139 (67)

0.08

Rate of infections/100 days (95% CI)†
All-cause mortality 28 days — no./total no. (%)
*

P values for all comparisons, except where noted, are two-sided mid-P values, based on an exact likelihood-ratio test.

†

Confidence intervals are exact two-sided 95% confidence intervals, and the P value is based on an exact test of homogeneity of event rates
between the hypothermia group and the normothermia group, assuming that event data follow Poisson distributions.
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